Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Elacestrant and PULSAR Radiotherapy in HR+ HER2- Breast Cancer
2025-520762-22-00Phase 2Authorised
- Sponsor
- Fondazione Radioterapia Oncologica
- Start
- Jul 2025
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elacestrant in breast cancer, sponsored by Fondazione Radioterapia Oncologica. Primary endpoints: Safety - AEs and SAEs and Safety - Clinical and laboratory parameters. Planned start Jul 2025; status: authorised.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-520762-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520762-22-00.